Wei LJ - Search Results

1

Quantifying the benefit of non-small-cell lung cancer immunotherapy.

Ludmir EB, McCaw ZR, Grossberg AJ, Wei LJ, Fuller CD. Ludmir EB, et al. Among authors: wei lj. Lancet. 2019 Nov 23;394(10212):1904. doi: 10.1016/S0140-6736(19)32503-6. Lancet. 2019. PMID: 31777387 No abstract available.

2

Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival Time.

McCaw ZR, Orkaby AR, Wei LJ, Kim DH, Rich MW. McCaw ZR, et al. Among authors: wei lj. Am J Med. 2019 Jan;132(1):13-15. doi: 10.1016/j.amjmed.2018.07.026. Epub 2018 Aug 1. Am J Med. 2019. PMID: 30076822 No abstract available.

3

Sex as a predictor of response to cancer immunotherapy.

Claggett B, Tian L, McCaw ZR, Takeuchi M, Wei LJ. Claggett B, et al. Among authors: wei lj. Lancet Oncol. 2018 Aug;19(8):e377. doi: 10.1016/S1470-2045(18)30517-5. Lancet Oncol. 2018. PMID: 30102227 Free PMC article. No abstract available.

4

Pembrolizumab plus Chemotherapy in Lung Cancer.

Sun R, Rich MW, Wei LJ. Sun R, et al. Among authors: wei lj. N Engl J Med. 2018 Sep 13;379(11):e18. doi: 10.1056/NEJMc1808567. N Engl J Med. 2018. PMID: 30211499 No abstract available.

5

Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.

McCaw ZR, Wei LJ, Kim DH. McCaw ZR, et al. Among authors: wei lj. N Engl J Med. 2018 Oct 25;379(17):1681. doi: 10.1056/NEJMc1810515. N Engl J Med. 2018. PMID: 30358968 No abstract available.

6

Body Composition and Overall Survival in Patients With Nonmetastatic Breast Cancer.

McCaw ZR, Liu D, Wei LJ. McCaw ZR, et al. Among authors: wei lj. JAMA Oncol. 2019 Jan 1;5(1):114-115. doi: 10.1001/jamaoncol.2018.5290. JAMA Oncol. 2019. PMID: 30476943 No abstract available.

7

Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective.

McCaw ZR, Piantadosi S, Wei LJ. McCaw ZR, et al. Among authors: wei lj. JAMA Surg. 2019 Mar 1;154(3):270-271. doi: 10.1001/jamasurg.2018.4294. JAMA Surg. 2019. PMID: 30484814 No abstract available.

8

Quantifying Immunoscore performance.

Sun R, Nie L, Huang B, Kim DH, Wei LJ. Sun R, et al. Among authors: wei lj. Lancet. 2018 Nov 3;392(10158):1624. doi: 10.1016/S0140-6736(18)32157-3. Lancet. 2018. PMID: 30496077 No abstract available.

9

Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)".

McCaw ZR, Tian L, Kim DH, Wei LJ. McCaw ZR, et al. Among authors: wei lj. Ann Surg. 2019 Aug;270(2):e48-e50. doi: 10.1097/SLA.0000000000003115. Ann Surg. 2019. PMID: 30499804 Free PMC article. No abstract available.

10

Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

McCaw ZR, Jiang F, Wei LJ. McCaw ZR, et al. Among authors: wei lj. JAMA Oncol. 2019 Jan 1;5(1):117-118. doi: 10.1001/jamaoncol.2018.5730. JAMA Oncol. 2019. PMID: 30520963 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

322 results

Search Page

Filters